Clinical Trial Update: Sirolimus as Primary Therapy for the Treatment of Chronic Graft Versus Host Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating sirolimus as primary therapy for chronic graft-versus-host disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Stanford University | Conditions: Graft vs Host Disease, Blood and Marrow Transplant (BMT) | Phase 2 | Status: COMPLETED